SmallCapReview: Small Cap Stocks To Watch - ITMTF, THLD, BLRX
Oct 16, 2012 (Menafn - M2 PRESSWIRE via COMTEX) --Goldman Small Cap Research announced Monday after market close, that it has issued research coverage of Intertainment Media (otcqx:ITMTF) 0.16, one of North America's leading technology incubators.
Intertainment Media is focused on developing, nurturing and investing in both North American and global technologies and companies that provide technology solutions for brands and consumers alike and then monetizing the asset through spin-outs on public exchanges or outright sales.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.
"Intertainment Media's strategy of unlocking significant value through the public spin-out or sale of key holdings could result in hundreds of millions in market value to investors. Ortsbo, Intertainment Media's crown jewel, is likely the first spinout target. The Company's model is tried and true and should result in a series of successes. A investment in INT is akin to a rare opportunity for investors to participate in the ownership of valuable, undervalued companies before they go public, via a venture fund-class type of vehicle."
What They Do: Intertainment Media is one of Canada's leading technology incubators and is focused on developing, nurturing and investing in both North American and global technologies and companies that provide technology solutions for brands and consumers alike.
Intertainment also owns and operates a number of key properties including Ad Taffy, itiBiti (KNCTR), Ortsbo, Deal Frenzy, The Sweet Card and Magnum, with investments in leading edge technologies and social media platforms including theaudience.com.
Threshold Pharmaceuticals THLD 5.25. Today announced that the U.S. Food and Drug Administration (FDA) has reached agreement with the U.S. affiliate of Merck KGaA, Darmstadt, Germany, Threshold's partner for the development and commercialization of TH-302, covering a Special Protocol Assessment (SPA) for a Phase 3 randomized trial of TH-302 in patients with metastatic or locally advanced unresectable pancreatic cancer.
The trial is designed to evaluate the efficacy and safety of TH-302 in combination with gemcitabine compared with gemcitabine therapy alone. Pursuant to Threshold's license and co-development agreement with Merck, Merck will be responsible for conducting the Phase 3 study under the SPA.
A Special Protocol Assessment (SPA) is a written agreement with the FDA that documents FDA's agreement that the design and planned analysis of a study can adequately address objectives in support of a regulatory submission. However, FDA's determinations for marketing application approval are made after a complete review of a marketing application and are based on the entire data in the application.
What They Do: Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies.
BioLineRx BLRX 3.05. Today announcedthat it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.Since in-licensing BL-8020 in January 2012, BioLineRx has successfully completed a number of pre-clinical studies with the therapy.
The data package is now ready for the regulatory submissions required to begin the clinical phase of development. BioLineRx is currently engaged in the regulatory submission process and expects to receive approval from the regulatory authorities by the end of this year.
What They Do: BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies.
Copyright SmallCapReview. SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit http://SmallCapReview.com to sign up for our FREE newsletter. SmallCapReview has been compensated three thousand five hundred dollars by a third party AWT for its efforts with regards to Intertainment Media.
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to email@example.com.
(C)1994-2012 M2 COMMUNICATIONS